Search Results - "Eichenfield, L"

The impact of airborne pollution on atopic dermatitis: a literature review by Hendricks, A.J., Eichenfield, L.F., Shi, V.Y.

“…Summary The increasing prevalence of atopic dermatitis (AD) parallels a global rise in industrialization and urban living over recent decades. This shift in…”
Get full text

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials by Simpson, E.L., Lacour, J.‐P., Spelman, L., Galimberti, R., Eichenfield, L.F., Bissonnette, R., King, B.A., Thyssen, J.P., Silverberg, J.I., Bieber, T., Kabashima, K., Tsunemi, Y., Costanzo, A., Guttman‐Yassky, E., Beck, L.A., Janes, J.M., DeLozier, A.M., Gamalo, M., Brinker, D.R., Cardillo, T., Nunes, F.P., Paller, A.S., Wollenberg, A., Reich, K.

“…Summary Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with…”
Get full text

Optimizing outcomes for paediatric atopic dermatitis by Eichenfield, L.F., Totri, C.

“…Summary Atopic dermatitis (AD) is considered the most prevalent chronic inflammatory condition in very young children, with a prevalence approaching 20% in…”
Get full text

Altered proliferation and networks in neural cells derived from idiopathic autistic individuals by Marchetto, M C, Belinson, H, Tian, Y, Freitas, B C, Fu, C, Vadodaria, K C, Beltrao-Braga, P C, Trujillo, C A, Mendes, A P D, Padmanabhan, K, Nunez, Y, Ou, J, Ghosh, H, Wright, R, Brennand, K J, Pierce, K, Eichenfield, L, Pramparo, T, Eyler, L T, Barnes, C C, Courchesne, E, Geschwind, D H, Gage, F H, Wynshaw-Boris, A, Muotri, A R

“…Autism spectrum disorders (ASD) are common, complex and heterogeneous neurodevelopmental disorders. Cellular and molecular mechanisms responsible for ASD…”
Get full text

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension by Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Hultsch, T., Davis, J.D., Zhang, Y., Zhu, X., Chen, Z., Li, M., Ardeleanu, M., Teper, A., Akinlade, B., Gadkari, A., Eckert, L., Kamal, M.A., Ruddy, M., Graham, N.M.H., Pirozzi, G., Stahl, N., DiCioccio, A.T., Bansal, A.

“…Summary Background Dupilumab (monoclonal antibody inhibiting IL‐4/IL‐13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately…”
Get full text

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study by Philipp, S., Menter, A., Nikkels, A.F., Barber, K., Landells, I., Eichenfield, L.F., Song, M., Randazzo, B., Li, S., Hsu, M.‐C., Zhu, Y., DePrimo, S., Paller, A.S.

“…Summary Background Limited options are available for treatment of paediatric psoriasis. Objectives To evaluate the efficacy and safety of ustekinumab in…”
Get full text

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study by Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Sun, X., Chen, Z., Akinlade, B., Boklage, S., Guillemin, I., Kosloski, M.P., Kamal, M.A., O’Malley, J.T., Patel, N., Graham, N.M.H., Bansal, A.

“…Summary Background Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16‐week, randomized,…”
Get full text

Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score by Stalder, J.‐F., Aubert, H., Anthoine, E., Futamura, M., Marcoux, D., Morren, M.‐A., Trzeciak, M., Szalai, Z., Veres, K., Deleuran, M., Vestergaard, C., Boralevi, F., Chu, C.‐Y., De Raeve, L., Svensson, Å., Fölster‐Holst, R., Buchner, M., Takaoka, R., Aoki, V., Chernyshov, P., Chernyshova, L., Murrell, D. F., Zhao, C., Mckinster, C. D., Von Kobyletzky, L., Eichenfield, L., Totri, C., Lio, P., Seneschal, J., Moret, L., Barbarot, S.

“…Background Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their…”
Get full text

Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne by Blume‐Peytavi, U., Fowler, J., Kemény, L., Draelos, Z., Cook‐Bolden, F., Dirschka, T., Eichenfield, L., Graeber, M., Ahmad, F., Alió Saenz, A., Rich, P., Tanghetti, E.

“…Background Treatment for both facial and truncal acne has not sufficiently been studied. Objectives To evaluate the long‐term safety and efficacy of…”
Get full text

Topical therapy of atopic dermatitis with a focus on pimecrolimus by Luger, T., Paller, A.S., Irvine, A.D., Sidbury, R., Eichenfield, L.F., Werfel, T., Bieber, T.

“…Atopic dermatitis (AD) is a chronic and relapsing, inflammatory skin disease characterized by impaired skin barrier function and immune system dysregulation…”
Get full text

Blistering severe cutaneous adverse reactions in children: proposal for paediatric‐focused clinical criteria by Ramien, M.L., Bahubeshi, A., Lara‐Corrales, I., Pope, E., Levy, M.L., Nopper, A.J., Shear, N.H., Eichenfield, L.

“…Severe cutaneous adverse reactions (SCARs) are challenging to diagnose and manage in children for two main reasons: 1) The literature on SCARs in children is…”
Get full text

Safety and efficacy of topical, fixed‐dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial by Eichenfield, L.F., Marcoux, D., Kurvits, M., Liljedahl, M.

“…Background Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical…”
Get full text

A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient‐Education Network in Dermatology (OPENED) task force by Misery, L., Belloni Fortina, A., El Hachem, M., Chernyshov, P., Kobyletzki, L., Heratizadeh, A., Marcoux, D., Aoki, V., Zaniboni, M.C., Stalder, J.‐F., Eichenfield, L.F.

“…Atopic dermatitis (AD) is a disease that can have a high impact on quality of life, especially due to itch and skin pain. This paper utilizes expertise from…”
Get full text

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials by Reich, K., DeLozier, A. M., Nunes, F. P., Thyssen, J. P., Eichenfield, L. F., Wollenberg, A., Ross Terres, J. A., Watts, S. D., Chen, Y.-F., Simpson, E. L., Silverberg, J. I.

“…Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient's quality of life (QoL). To…”
Get full text

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion by Thyssen, J.P., Bruin‐Weller, M.S., Paller, A.S., Leshem, Y.A., Vestergaard, C., Deleuran, M., Drucker, A.M., Foelster‐Holst, R., Traidl‐Hoffmann, C., Eyerich, K., Taieb, A., Su, J.C., Bieber, T., Cork, M.J., Eichenfield, L.F., Guttman‐Yassky, E., Wollenberg, A.

“…Background Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with…”
Get full text

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries by Vermeulen, F.M., Gerbens, L.A.A., Bosma, A.L., Apfelbacher, C.J., Irvine, A.D., Arents, B.W.M., Barbarot, S., Deleuran, M., Eichenfield, L.F., Manca, A., Schmitt, J., Vestergaard, C., Wall, D., Weidinger, S., Middelkamp‐Hup, M.A., Spuls, P.I., Flohr, C.

“…Summary Background Comparative, real‐life and long‐term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate‐to‐severe…”
Get full text

Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment by Ovejero, D., Lim, Y. H., Boyce, A. M., Gafni, R. I., McCarthy, E., Nguyen, T. A., Eichenfield, L. F., DeKlotz, C. M. C., Guthrie, L. C., Tosi, L. L., Thornton, P. S., Choate, K. A., Collins, M. T.

“…Summary Cutaneous skeletal hypophosphatemia syndrome (CSHS), caused by somatic RAS mutations, features excess fibroblast growth factor-23 (FGF23) and skeletal…”
Get full text

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials by Gottlieb, A.B., Gordon, K., Hsu, S., Elewski, B., Eichenfield, L.F., Kircik, L., Rastogi, S., Pillai, R., Israel, R.

“…Background Patients with psoriasis have lesional symptoms, including itch, which can reduce quality of life. The efficacy and safety of brodalumab, an…”
Get full text

TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries by Gerbens, L.A.A., Apfelbacher, C.J., Irvine, A.D., Barbarot, S., Booij, R.J., Boyce, A.E., Deleuran, M., Eichenfield, L.F., Hof, M.H., Middelkamp‐Hup, M.A., Roberts, A., Schmitt, J., Vestergaard, C., Wall, D., Weidinger, S., Williamson, P.R., Flohr, C., Spuls, P.I.

“…Summary Background Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE) is scarce, despite frequent and often off‐label…”
Get full text

A systematic review of the safety of topical therapies for atopic dermatitis by Callen, J., Chamlin, S., Eichenfield, L.F., Ellis, C., Girardi, M., Goldfarb, M., Hanifin, J., Lee, P., Margolis, D., Paller, A.S., Piacquadio, D., Peterson, W., Kaulback, K., Fennerty, M., Wintroub, B.U.

“…Summary Background  The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny,…”
Get full text